Silexion Therapeutics Corp has seen significant tumor inhibition in pre-clinical studies across pancreatic, colorectal, and lung cancer models with their SIL204 therapeutic platform. They plan to start a Phase 2/3 clinical trial in LAPC in H1 of 2026 after successful toxicology studies and positive regulatory feedback. The company aims to address the $30+ billion global KRAS-driven cancer market with their innovative RNA interference therapies. In 2025, Silexion made substantial progress, positioning SIL204 for human clinical trials in 2026 and potentially revolutionizing cancer treatment for KRAS-driven cancers.

Read more at GlobeNewswire: Silexion Therapeutics Releases CEO Letter to Shareholders